Oludamilola W Oluleye1, Thomas S Rector1, Sithu Win1, John J V McMurray1, Michael R Zile1, Michel Komajda1, Robert S McKelvie1, Barry Massie1, Peter E Carson1, Inder S Anand2. 1. From the Department of Medicine, VA Medical Center and University of Minnesota, Minneapolis (O.W.O., T.S.R., S.W., I.S.A.); Institute of Cardiovascular and Medical Sciences, British Heart Foundation Glasgow Cardiovascular Research Centre, Glasgow, United Kingdom (J.J.V.M.); Department of Medicine, RHJ Department of Veterans Affairs Medical Center, Medical University of South Carolina, Charleston (M.R.Z.); Institut de Cardiologie, Université Paris 6, Pitie Salpetriere Hospital, Paris, France (M.K.); Department of Medicine, Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada (R.S.M.); Department of Medicine, San Francisco Veterans Affairs Medical Center, University of California (B.M.); and Department of Medicine, Washington VAMC and Georgetown University, Washington, DC (P.E.C.). 2. From the Department of Medicine, VA Medical Center and University of Minnesota, Minneapolis (O.W.O., T.S.R., S.W., I.S.A.); Institute of Cardiovascular and Medical Sciences, British Heart Foundation Glasgow Cardiovascular Research Centre, Glasgow, United Kingdom (J.J.V.M.); Department of Medicine, RHJ Department of Veterans Affairs Medical Center, Medical University of South Carolina, Charleston (M.R.Z.); Institut de Cardiologie, Université Paris 6, Pitie Salpetriere Hospital, Paris, France (M.K.); Department of Medicine, Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada (R.S.M.); Department of Medicine, San Francisco Veterans Affairs Medical Center, University of California (B.M.); and Department of Medicine, Washington VAMC and Georgetown University, Washington, DC (P.E.C.). anand001@umn.edu.
Abstract
BACKGROUND: Atrial fibrillation (AFib) is common in heart failure (HF) with preserved ejection fraction (HFpEF). Current AFib stroke risk prediction models include the presence of HF but do not specifically include HFpEF as a risk factor. Whether a history of AFib should be used to identify patients with HFpEF who are at risk has not been established. METHODS AND RESULTS: Baseline characteristics and outcomes of patients with HFpEF in the Irbesartan in Heart Failure with Preserved Ejection Fraction Trial were analyzed in relation to AFib. At baseline, 1209 (29.3%) had a history of AFib. Of these 557 (13.5%) had history of AFib alone, whereas 670 (16.2%) had both a history and AFib on ECG; 2901 (70.3%) had neither. There were no significant differences in the risk of stroke between the 2 groups with a history of AFib who did or did not have AFib present on baseline ECG. During a median follow-up of 53 months, a fatal or nonfatal stroke occurred in 6.5% (79/1209) patients with history of AFib compared with 3.9% (114/2901) with no AFib. Having a history of AFib was independently associated with higher risk of stroke (hazard ratio, 2.2; 95% confidence interval, 1.6-3.2; P<0.0001) compared with those with no history of AFib. CONCLUSIONS: In patients with HFpEF, a history of AFib was common and independently associated with increased risk of stroke, regardless of whether AFib was present on ECG. Patients with HFpEF and a history of AFib should be considered at risk. Further studies are needed to determine whether this risk can be safely reduced. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT000095238.
RCT Entities:
BACKGROUND:Atrial fibrillation (AFib) is common in heart failure (HF) with preserved ejection fraction (HFpEF). Current AFib stroke risk prediction models include the presence of HF but do not specifically include HFpEF as a risk factor. Whether a history of AFib should be used to identify patients with HFpEF who are at risk has not been established. METHODS AND RESULTS: Baseline characteristics and outcomes of patients with HFpEF in the Irbesartan in Heart Failure with Preserved Ejection Fraction Trial were analyzed in relation to AFib. At baseline, 1209 (29.3%) had a history of AFib. Of these 557 (13.5%) had history of AFib alone, whereas 670 (16.2%) had both a history and AFib on ECG; 2901 (70.3%) had neither. There were no significant differences in the risk of stroke between the 2 groups with a history of AFib who did or did not have AFib present on baseline ECG. During a median follow-up of 53 months, a fatal or nonfatal stroke occurred in 6.5% (79/1209) patients with history of AFib compared with 3.9% (114/2901) with no AFib. Having a history of AFib was independently associated with higher risk of stroke (hazard ratio, 2.2; 95% confidence interval, 1.6-3.2; P<0.0001) compared with those with no history of AFib. CONCLUSIONS: In patients with HFpEF, a history of AFib was common and independently associated with increased risk of stroke, regardless of whether AFib was present on ECG. Patients with HFpEF and a history of AFib should be considered at risk. Further studies are needed to determine whether this risk can be safely reduced. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT000095238.
Authors: Theodora Nikolaidou; Nathan A Samuel; Carl Marincowitz; David J Fox; John G F Cleland; Andrew L Clark Journal: Ann Noninvasive Electrocardiol Date: 2019-10-11 Impact factor: 1.468